Cronos Group Inc. (CRON) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Cronos Group Inc. (CRON) stock forecast summary
On Oct. 16, 2026, CRON is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
Cronos Group Inc. is a small-cap company with a market capitalization of $1.18B. It ranks number 3 by market capitalization among the 29 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast. Its Current Ratio of 16.18x is the highest of the 29 peers that report one. Its D/E Ratio of 0.06x is the lowest of the 17 peers that report one.
For CRON, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -21.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -15.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CRON included.
Follow CRON freeCRON price chart and AI forecast
How CRON ranks among 5184 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Cronos Group Inc. (CRON) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | CRON | Rank |
|---|---|---|
| Market Cap | $1.18B | 3/29 |
| P/E Ratio | 18.88x | 2/6 |
| P/B Ratio | 1.11x | 7/13 |
| EPS | $0.17 | – |
| Book Value/Share | $2.90 | – |
| Revenue/Share | $0.64 | – |
| FCF/Share | $0.14 | – |
Profitability & Margins
| Metric | CRON | Rank |
|---|---|---|
| ROE | 6.5% | 3/16 |
| ROA | 5.9% | 4/25 |
| ROIC | -0.2% | 9/21 |
| Gross Margin | 34.7% | 16/23 |
| Operating Margin | -1.0% | 7/24 |
| Net Margin | 29.6% | 2/22 |
| EBT Margin | 28.9% | 2/25 |
| Tax Rate | -15.7% | – |
Financial Health
| Metric | CRON | Rank |
|---|---|---|
| Current Ratio | 16.18x | 1/29 |
| Quick Ratio | 15.25x | 1/26 |
| D/E Ratio | 0.06x | 17/17 |
| Financial Leverage | 1.10x | 17/17 |
| Interest Coverage | 34.4x | 3/22 |
| Working Capital | $856M | 2/29 |
Cash Flow
| Metric | CRON | Rank |
|---|---|---|
| Operating Cash Flow | $60M | 2/30 |
| Free Cash Flow | $50M | 2/12 |
| Capital Spending | -$10M | 7/12 |
| OCF Growth YoY | 199.9% | 2/11 |
| FCF/Sales | 21.0% | 1/12 |
| CapEx/Sales | 4.3% | 4/12 |
Operational Efficiency
| Metric | CRON | Rank |
|---|---|---|
| Asset Turnover | 0.20x | 17/17 |
| Receivables Turnover | 6.5x | 14/16 |
| Fixed Assets Turnover | 1.7x | 14/17 |
| Days Sales Outstanding | 57 days | 3/16 |
Income Statement
| Metric | CRON | Rank |
|---|---|---|
| Total Revenue | $237M | 8/18 |
| Operating Income | -$2M | 14/28 |
| Net Income | $70M | 1/25 |
| R&D Expense | $5M | 5/9 |
| SG&A Expense | $81M | 6/16 |
Dividend & Shareholder Information
| Metric | CRON | Rank |
|---|---|---|
| Shares Outstanding | 368M | – |
| Net Income Growth | 278.5% | 1/5 |
| EPS Growth | 466.7% | 1/7 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $912M | 77.3% of assets |
| Cash & Short-term Investments | $467M | 39.6% of assets |
| Accounts Receivable | $37M | 3.1% of assets |
| Inventory | $53M | 4.5% of assets |
| Total Liabilities | $62M | 5.3% of assets |
| Short-term Debt | $39M | 3.3% of assets |
CRON quarterly financials and insider trading
Cronos Group Inc. (CRON) industry peers
Companies classified under the same SEC industry code as Cronos Group Inc. (Medicinal Chemicals & Botanical Products): 33 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| CRON Cronos Group Inc. | ▶ | $1.18B |
| DFTX Definium Therapeutics, Inc. | ▲ | $4.31B |
| TRLV Trulieve Cannabis Corp. | ▶ | $1.93B |
| TLRY Tilray Brands, Inc. | ▶ | $414M |
| SNDL Sndl Inc. | ▶ | $322M |
| CGC Canopy Growth Corp | ▶ | $302M |
| GLAS Glass House Brands Inc. | ▼ | $301M |
| USNA Usana Health Sciences Inc | ▼ | $287M |
| ACB Aurora Cannabis Inc | ▶ | $253M |
| NAGE Niagen Bioscience, Inc. | ▶ | $197M |
| MDWD Mediwound Ltd. | ▶ | $152M |
| AAWH Ascend Wellness Holdings, Inc. | ▲ | $80M |
| FTLF Fitlife Brands, Inc. | ▶ | $79M |
| BTMD Biote Corp. | ▲ | $35M |
| RAPH Raphael Pharmaceutical Inc. | ▼ | $30M |
| CHUC Charlie's Holdings, Inc. | ▶ | $27M |
| MRMD Marimed Inc. | ▲ | $24M |
| CFOO China Foods Holdings Ltd. | ▼ | $21M |
| MTEX Mannatech Inc | ▲ | $14M |
| ADIA Adia Med, Inc. | ▲ | $13M |
| GLUC Glucose Health, Inc. | ▼ | $9M |
| NAII Natural Alternatives International Inc | ▲ | $7M |
| BON Bon Natural Life Ltd | ▼ | $7M |
| PLSH Panacea Life Sciences Holdings, Inc. | ▲ | $6M |
| CYAN Cyanotech Corp | ▲ | $5M |
| IMCC Im Cannabis Corp. | ▼ | $2M |
| AIBT Aibotics, Inc. | ▼ | $2M |
| NPHC Nutra Pharma Corp | ▼ | $720K |
| MEHA Functional Brands Inc. | ▼ | $290K |
| CBDY Target Group Inc. | ▼ | N/A |
| HYEX Healthy Extracts Inc. | ▲ | N/A |
| NTRR Neutra Corp. | ▼ | N/A |
| SNYRQ Synergy Chc Corp. | ▼ | N/A |
Where CRON sits on the market map
Cronos Group Inc. (CRON) stock news
Loading...
Cronos Group Inc. (CRON) stock forecast FAQ
What is the Cronos Group Inc. (CRON) stock forecast?
On Oct. 16, 2026, CRON is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
How accurate are Cronos Group Inc. stock predictions?
For CRON, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -21.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -15.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Cronos Group Inc. forecasts updated?
Cronos Group Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Cronos Group Inc.'s industry peers?
33 issuers in our coverage, CRON included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Canopy Growth Corp (CGC), Glass House Brands Inc. (GLAS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.